OncoGenex' Candidate Progresses

Zacks

OncoGenex Pharmaceuticals, Inc. (OGXI) recently announced that it is looking to move its oncology candidate, OGX-427, into a phase II study, Borealis-2, for the potential treatment of advanced or metastatic bladder cancer.

The investigator-sponsored, randomized, controlled phase II study will enroll 200 patients suffering from advanced or metastatic bladder cancer whose disease has progressed following initial platinum-based chemotherapy treatment.

This study will evaluate OGX-427 plus Sanofi’s (SNY) Taxotere (docetaxel) in improving survival compared to Taxotere alone.

OGX-427 is also in another clinical trial, Borealis-1. A randomized, placebo-controlled phase II study, Borealis-1 is designed to evaluate the potential survival benefit, safety and tolerability of combining OGX-427 with gemcitabine and cisplatin in the first-line treatment of patients with advanced bladder cancer.

OncoGenex will decide on a phase III study of OGX-427 in bladder cancer if one of these two studies shows a survival advantage.

The most advanced candidate in OncoGenex’s pipeline is custirsen (phase III) under evaluation for the treatment of metastatic castrate-resistant prostate cancer in men and also for the treatment of patients with advanced, unresectable non-small cell lung cancer. OncoGenex has a global collaboration and license agreement with Teva Pharmaceutical Industries Ltd. (TEVA) to develop and commercialize the candidate. Another candidate, OGX-225, for the solid tumors indication is in pre-clinical development.

OncoGenex and Teva currently carry a Zacks Rank #3 (Hold). Right now, Furiex Pharmaceuticals, Inc. (FURX) looks more attractive with a Zacks Rank #1 (Strong Buy).

Read the Full Research Report on SNY

Read the Full Research Report on TEVA

Read the Full Research Report on OGXI

Read the Full Research Report on FURX

Zacks Investment Research



More From Zacks.com

Rates

View Comments (0)